| Document Date: 2014-05-05 01:00:30
Open Document File Size: 253,18 KBShare Result on Facebook
City Hyderabad / Lyon / New York / Paris / / Company Shantha / Sanofi Pasteur Holding / Sanofi Pasteur / Genzyme / / Country France / India / / Currency EUR / / Event M&A / Company Listing Change / / IndustryTerm manufacturing facility / human health care products / biotechnology pioneer / therapeutic solutions / consumer healthcare / manufacturing facilities / manufacturing platform / manufacturing / healthcare / integrated biotechnology / diabetes solutions / / MedicalCondition Shanvac-B® hepatitis B / ShanTT™ tetanus / pertussis / whole-cell pertussis / diphtheria / tetanus / hepatitis B. Shan5 / diabetes / Shanchol™ cholera / diseases / polio eradication / infectious diseases / / MedicalTreatment vaccination / / Organization World Health Organization / United Nations / United Nations International Children's Emergency Fund / Shantha’s mission / / Person Olivier Charmeil / Harish Iyer / / Position CEO / leader / President and CEO / integrated global healthcare leader / / Product Shan5 / / Technology biotechnology / therapeutic solutions / /
SocialTag |
PRESS RELEASE Shantha’s Pentavalent Pediatric Vaccine prequalified by World Health Organization - Shan5™ is the first vaccine jointly developed by the Indian company and its parent company Sanofi Pasteur - WHO’s d